TRVI (Trevi Therapeutics) Days Inventory: 0.00 (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

TRVI Trevi Therapeutics Inc TRVI
22 GF Score
Price $17.80
! 3 Warning Signs
View Full Analysis

What is Trevi Therapeutics Days Inventory?

Trevi Therapeutics TRVI -3.73% 22 Days Inventory is 0.00 as of Jun. 2026. GuruFocus rates TRVI with a GF Score™ of 22/100. The stock has 3 warning signs investors should review. Among 638 Biotechnology companies, Trevi Therapeutics ranks worse than 156739.66% on this metric.

Days Inventory is also known as Days Sales of Inventory (DSI). Trevi Therapeutics's Average Total Inventories for the three months ended in Jun. 2026 was $0.00 Mil. Trevi Therapeutics's Cost of Goods Sold for the three months ended in Jun. 2026 was $0.00 Mil.

The historical rank and industry rank for Trevi Therapeutics's Days Inventory or its related term are showing as below:

TRVI's Days Inventory is not ranked *
in the Biotechnology industry.
Industry Median: 179.22
* Ranked among companies with meaningful Days Inventory only.

Trevi Therapeutics's Days Inventory stayed the same from Jun. 2025 (0.00) to Jun. 2026 (0.00).

Inventory Turnover measures how fast the company turns over its inventory within a year.

Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.


Trevi Therapeutics  (NAS:TRVI) Days Inventory Explanation

Days Inventory indicates the liquidity of the inventory. Generally, a lower Days Inventory is preferred as it indicates a shorter duration to clear off the inventory. An increase of the ratio may indicate the company's sales slowed. Similar ratios related to Days Inventory are:

1. Inventory Turnover measures how fast the company turns over its inventory within a year.

Trevi Therapeutics's Inventory Turnover for the three months ended in Jun. 2026 is calculated as

2. Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.

Trevi Therapeutics's Inventory to Revenue for the three months ended in Jun. 2026 is calculated as

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Be Aware

A lot of business are seasonable. It makes more sense to compare Days Inventory from the same period in the previous year instead of from the previous quarter.


Trevi Therapeutics Days Inventory Related Terms


Trevi Therapeutics Days Inventory Historical Data

* Premium members only.

The historical data trend for Trevi Therapeutics's Days Inventory can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Trevi Therapeutics Days Inventory Chart

Trevi Therapeutics Annual Data
Trend Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Days Inventory
Get a 7-Day Free Trial Premium Member Only 0.00 0.00 0.00 0.00 0.00

Trevi Therapeutics Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Days Inventory Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

TRVI vs IMNM, VERA, NRIX: Days Inventory Comparison

For the Biotechnology subindustry, Trevi Therapeutics's Days Inventory, along with its competitors' market caps and Days Inventory data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Trevi Therapeutics Days Inventory vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Trevi Therapeutics's Days Inventory distribution charts can be found below:

* The bar in red indicates where Trevi Therapeutics's Days Inventory falls into.


TRVI
22GF Score
Trevi Therapeutics Inc TRVI
Days Inventory is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Trevi Therapeutics Days Inventory Calculation

Days Inventory indicates the number of days of goods in sales that a company has in the inventory.

Trevi Therapeutics's Days Inventory for the fiscal year that ended in Dec. 2025 is calculated as

Days Inventory (A: Dec. 2025 )
=Average Total Inventories / Cost of Goods Sold*Days in Period
=( (Total Inventories (A: Dec. 2024 ) + Total Inventories (A: Dec. 2025 )) / count ) / Cost of Goods Sold (A: Dec. 2025 )*Days in Period
=( (0 + 0) / 1 ) / 0*365
=0 / 0*365
=N/A

Trevi Therapeutics's Days Inventory for the quarter that ended in Jun. 2026 is calculated as:

Days Inventory (Q: Jun. 2026 )
=Average Total Inventories / Cost of Goods Sold*Days in Period
=( (Total Inventories (Q: Mar. 2026 ) + Total Inventories (Q: Jun. 2026 )) / count ) / Cost of Goods Sold (Q: Jun. 2026 )*Days in Period
=( (0 + 0) / 1 ) / 0*365 / 4
=0 / 0*365 / 4
=N/A

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Days Inventory →
What does a Days Inventory of 0.00 mean?
Trevi Therapeutics (TRVI) has a Days Inventory of 0.00 as of Jun. 2026. Days inventory represents the average amount of days a company holds inventory before selling it. View historical data on Trevi Therapeutics and its competitors. According to the industry distribution chart, Trevi Therapeutics ranks #999999 out of 638 companies in the Biotechnology industry.
Is Trevi Therapeutics' Days Inventory too high?
Trevi Therapeutics' current Days Inventory is 0.00. Based on the distribution chart, Trevi Therapeutics ranks #999999 out of 638 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Trevi Therapeutics has a GF Score™ of 22/100, reflecting its overall financial health beyond just this single metric.
How does Trevi Therapeutics' Days Inventory compare to IMNM and VERA?
According to the Biotechnology industry distribution chart, Trevi Therapeutics ranks #999999 out of 638 companies for Days Inventory. This places Trevi Therapeutics in the lower half of its industry. The industry median Days Inventory is 179.22. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Inventory for a Biotechnology company?
The median Days Inventory among Biotechnology companies is 179.22, based on 638 companies in the industry. Companies in the top quartile (top 25%) have a Days Inventory significantly above this median, while those in the bottom quartile fall well below. However, Days Inventory should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Inventory mean?
A high Days Inventory can signal that a stock is expensive relative to its fundamentals. Days inventory represents the average amount of days a company holds inventory before selling it. View historical data on Trevi Therapeutics and its competitors. For the Biotechnology industry, the median Days Inventory is 179.22 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Trevi Therapeutics's current Days Inventory is 0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Trevi Therapeutics stock overvalued right now?
Trevi Therapeutics (TRVI) has a current Days Inventory of 0.00. The current Days Inventory is 0.00. Trevi Therapeutics' overall GF Score™ is 22/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Inventory calculated?
Days Inventory is calculated from a company's financial statements. For Trevi Therapeutics (TRVI), the current Days Inventory is 0.00 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Trevi Therapeutics Business Description

Address 195 Church Street, 16th Floor, New Haven, CT, USA, 06510
Trevi Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the development and commercialization of the investigational therapy Haduvio (oral nalbuphine ER) for the treatment of chronic cough in adults with idiopathic pulmonary fibrosis, or IPF, non-IPF interstitial lung disease, or non-IPF ILD, and refractory chronic cough, or RCC. Haduvio is an oral extended-release formulation of nalbuphine. The Company operates and manages its business as one reportable segment. Such a segment is the business of developing and commercializing the investigational therapy Haduvio.
22GF Score

Get the complete analysis for TRVI

Days Inventory is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$17.80
Price